体外扩增CIK细胞杀伤胃癌细胞SGC-7901

目的：观察CIK细胞增殖情况，了解扩增后的最佳应用时机，并观察体外对SGC-7901的杀伤作用。方法：健康人外周血单核细胞（PBMC）在体外条件下经过多种细胞因子的共同刺激诱导成CIK细胞，计数培养不同时间的CIK细胞，用流式细胞术检测CIK细胞的表型特征。用MTT法检测杀伤活性，对比CIK细胞与5-FU对SGC-7901的杀伤作用，并观察了两者联合应用的效果。结果：CIK细胞随体外培养时间的延长，数量及杀伤活性均增加。体外培养20d增殖124倍，CD3^＋、CD56^＋双阳性细胞的比例达66．1％，其后两者数量增长缓慢；体外实验显示CIK细胞对胃癌SGC-7901细胞株有明显的杀伤作用，最高杀伤效率为73．13％，其杀伤作用优于5-FU，P〈0．05。二者联合应用杀伤作用降低。结论：CIK细胞具有较强的抗胃癌细胞活性；体外培养15～20d时应用较为合适；联合应用时5-FU可降低CIK细胞的杀伤效率。

Proliferation profile and anti-tumor effects of CIK cells against gastric cancer cell lines SGC-7901 in vitro

OBJECTIVE: To observe the proliferation ability of CIK (cytokine-induced killer) cells from healthy donor and decide the suitable time for clinical application, and to investigate the anti-tumor effects against gastric cancer cell lines SGC-7901 in vitro. METHODS: Mononuclear cells were isolated from peripheral blood with ficoll solution. CIK cells from PBMC were induced with different cytokines, the proliferation ability of CIK cells was measured by calculation in different culturing time, and the phenotype of CIK cells was analyzed by a flow cytometer. Compared with 5-FU, the antitumor cytotoxicity of CIK cells was measured by MTT assay, and the anti-tumor effects of CIK cells combined with 5-FU were investigated. RESULTS: CIK cells possessed strong proliferate ability with over 124-flod expansion after 20 days culture, CD3+ CD56+ cells had a significant increase and the percentage was 66.1% after 20 days' culture. But then, both the proliferate ability of CIK cells and the percentage of CD3+ CD56+ cells declined. CIK cells possessed significantly higher ability to kill tumor cells than 5-FU (P<0.05) and the anti-tumor effects of CIK cells declined combined with 5-FU. CONCLUSIONS: CIK cells are highly efficient cytotoxicity effector cells which have a stronger significant suppression against growth of carcinoma of stomach in vitro. It is a suitable time for clinical application at day 15 to 20,which is the proliferation peak. 5-FU can decline the antitumor cytotoxicity of CIK cells.